<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02309671</url>
  </required_header>
  <id_info>
    <org_study_id>000124</org_study_id>
    <nct_id>NCT02309671</nct_id>
  </id_info>
  <brief_title>A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment</brief_title>
  <official_title>A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial Assessing the Dose-response Relationship of FE 999049 in Controlled Ovarian Stimulation in Japanese Women Undergoing an Assisted Reproductive Technology Programme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates the effects of several doses of FE 999049 in Japanese women
      undergoing IVF/ICSI treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>End of stimulation (max 16 days after investigational medicinal product (IMP) start)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of follicles during stimulation</measure>
    <time_frame>Up to 16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of follicles during stimulation</measure>
    <time_frame>Up to 16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine profile measured by circulating levels of hormones</measure>
    <time_frame>Up to 16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total IMP dose administered measured from first until last dose (end of stimulation)</measure>
    <time_frame>Up to 16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo quality measured by fertilised oocytes and number and quality of embryos and blastocysts during culturing</measure>
    <time_frame>5 days (from oocyte retrieval to embryo transfer)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful pregnancy rate</measure>
    <time_frame>5-6 weeks after transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>From signing informed consent form until end of trial visit = 8-9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of adverse events</measure>
    <time_frame>From signing informed consent form until end of trial visit = 8-9 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>FE 999049 6 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 999049 9 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 999049 12 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLLISTIM 150 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>follitropin beta</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FE 999049</intervention_name>
    <arm_group_label>FE 999049 6 µg</arm_group_label>
    <arm_group_label>FE 999049 9 µg</arm_group_label>
    <arm_group_label>FE 999049 12 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>follitropin beta</intervention_name>
    <arm_group_label>FOLLISTIM 150 IU</arm_group_label>
    <other_name>FOLLISTIM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women diagnosed with tubal infertility, unexplained infertility, infertility related
             to endometriosis stage I/II or with partners diagnosed with male factor infertility

          -  Women eligible for IVF and/or ICSI treatment

          -  Women aged 20-39 years

          -  Women with body mass index (BMI) of 17.5-32.0 kg/m2

        Exclusion Criteria:

          -  Women with polycystic ovary syndrome (PCOS) associated with anovulation, endometriosis
             stage III/IV

          -  Women with history of recurrent miscarriage

          -  Women with contraindications to controlled ovarian stimulation with gonadotropins

          -  Women with three or more controlled ovarian stimulation cycles
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational site (there may be other sites in this country)</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2014</study_first_submitted>
  <study_first_submitted_qc>December 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <disposition_first_submitted>November 4, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>November 4, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 7, 2016</disposition_first_posted>
  <last_update_submitted>November 4, 2016</last_update_submitted>
  <last_update_submitted_qc>November 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

